Search clinical trials for: Prednisone Everolimus

Total 3502 results

Janssen Research & Development, LLC

Terminated

A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)

Prostatic Neoplasms

United States, Canada
Merck KGaA, Darmstadt, Germany

Completed

Prednisone Timed-Release Tablet (TRT) Study: Modified-Release (MR) Formulation of Prednisone Compared to Standard Immediate-Release (IR) Prednisone in Participants With Rheumatoid Arthritis

Rheumatoid Arthritis

Poland, Germany
Umberto I Hospital, Frosinone Italy

Unknown

Study of ABSORB Stent in Acute Myocardial Infarction (ABSORB-ACS)

Acute Myocardial Infarction | Artery; Deformity, Coronary (Acquired)

Italy
Novartis Pharmaceuticals

No longer available

MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer

Advanced Hormone Receptor Positive (HR+) Breast Cancer
Dana-Farber Cancer Institute
Novartis; Pediatric Oncology Experimental Therapeutics Investigators' Consortium

Completed

Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas

Glioma | Astrocytoma | Low-grade Glioma

United States
Yonsei University

Completed

A Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II)

Epilepsy and Focal Cortical Dysplasia II

Korea, Republic of
Cardiff University
Novartis

Unknown

A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous Sclerosis (TRON)

Tuberous Sclerosis

United Kingdom
Julie E. Bauman, MD, MPH
Novartis

Terminated

Phase II Study of RAD001 Head and Neck Cancer

Squamous Cell Carcinoma of the Head and Neck

United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib

Metastatic Renal Cell Carcinoma (mRCC)

Germany
Abbott Medical Devices

Completed

XIENCE V® Everolimus Eluting Coronary Stent System India Post-marketing Single-arm Study (XIENCE V India)

Coronary Artery Disease | Coronary Disease | Coronary Restenosis

India
Abbott Medical Devices

Completed

SPIRIT V: Post-marketing Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in Europe (SPIRIT V)

Coronary Artery Disease | Coronary Disease | Coronary Restenosis

Ireland, Netherlands, Singapore, Spain, China, Belgium, Switzerland, Thailand, Israel, Germany, New Zealand, United Kingdom, Italy, Malaysia, Canada, India, Austria, France, South Africa, Portugal, Czech Republic, Greece, Sweden
AIO-Studien-gGmbH
Novartis Pharmaceuticals; Assign Data Management and Biostatistics GmbH

Completed

Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study (EVINEC)

Neuroendocrine Carcinoma, Grade 3 | Poorly Differentiated Malignant Neuroendocrine Carcinoma | Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3 | Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma]... and other conditions

Germany
Radboud University Medical Center
Novartis

Completed

Influence of Exceptional Patient Characteristics on Everolimus Exposure (INPRES)

Breast Neoplasms

Netherlands
Novartis Pharmaceuticals

Completed

An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)

Neuroendocrine Tumors

Germany
Hopital Foch

Completed

The Efficacy of RAD 001 as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the Urothelium (AFINIVEST)

Urothelial Cancer

France
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors (RADIANT-3)

Advanced Neuroendocrine Tumors of Pancreatic Origin

Canada, France, United Kingdom, Taiwan, Belgium, Spain, Netherlands, United States, Italy, Sweden, Switzerland, Thailand, Germany, Greece, Korea, Republic of, Japan, Brazil, Slovakia
Mamta Parikh
National Cancer Institute (NCI)

Recruiting

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

Stage IV Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Advanced Prostate Adenocarcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer

Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Prostate Carcinoma Metastatic in the Bone

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Prostate Adenocarcinoma Without Neuroendocrine Differentiation

United States
Yonsei University

Unknown

A Randomized Comparison of Clinical Outcomes Between Everolimus-eluting Bioresorbable Vascular Scaffold Versus Everolimus-eluting Metallic Stent in Long Coronary Lesions

Coronary Artery Disease

Korea, Republic of
Seattle Children's Hospital
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaborators

Completed

Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis

Juvenile Idiopathic Arthritis | Juvenile Rheumatoid Arthritis | Juvenile Chronic Polyarthritis

United States
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center; Massachusetts General Hospital; Novartis; MOUNT SINAI...

Completed

RAD001 for Patients With Radioiodine Refractory Thyroid Cancer

Thyroid Cancer

United States
Novartis Pharmaceuticals

Completed

Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer

Breast Neoplasms | Neoplasm Metastasis

Belgium, Italy, Poland, Sweden, France
Abbott Medical Devices

Terminated

The ABSORB BTK (Below The Knee) Clinical Investigation

Atherosclerosis | Peripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Claudication | Critical Limb Ischemia | PAD | PVD | Lower Limb Disease | PAOD

Belgium
Linda C. Higgins
University of Texas Southwestern Medical Center

Terminated

Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal

Kidney Cancer

United States
Academisch Medisch Centrum - Universiteit van Amsterdam...
Erasmus Medical Center

Withdrawn

Study of Everolimus in the Treatment of Advanced Malignancies in Patients With Peutz-Jeghers Syndrome (EVAMP)

Neoplasm Metastasis | Neoplastic Processes | Peutz-Jeghers Syndrome

Netherlands
Seagen Inc.

Terminated

A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma

Renal Cell Carcinoma

United States
North Texas Veterans Healthcare System

Completed

AngiographiC Evaluation of the Everolimus-Eluting Stent in Chronic Total Occlusions - the ACE-CTO Study (ACE-CTO)

Coronary Occlusions

United States
Children's Hospital Medical Center, Cincinnati
Novartis

Completed

Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM)

Tuberous Sclerosis | Angiolipoma

United States
Samsung Medical Center

Completed

Combination Anticancer Therapy of Paclitaxel and Everolimus for Relapsed or Refractory Small Cell Lung Cancer

Small Cell Lung Cancer

Korea, Republic of
Technical University of Munich

Completed

Combination of Nilotinib (AMN107) and RAD001 in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

Germany
University of Chicago
Novartis Pharmaceuticals

Terminated

Everolimus Versus Placebo in Head and Neck Cancer

Head and Neck Cancer

United States
Yonsei University

Completed

Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer

Head and Neck Cancer

Korea, Republic of
Institut National de la Santé Et de la Recherche...

Terminated

A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma

Kaposi Sarcoma

France
Bausch & Lomb Incorporated

Completed

Study of T-PRED(TM) Compared to Pred Forte(R)

Cataract

United States
Abbott Medical Devices

Completed

ABSORB II Randomized Controlled Trial (ABSORB II)

Coronary Artery Disease

Belgium
Novartis Pharmaceuticals

Completed

SOCRATES: Steroid or Cyclosporine Removal After Transplantation Using Everolimus

Renal Transplanted Recipients

Australia
Samsung Medical Center
National Cancer Center, Korea; Asan Medical Center; Yonsei University; Korea Cancer...

Completed

RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas (RADCHOP)

Cutaneous T Cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-negative | Angioimmunoblastic T Cell Lymphoma | Peripheral T Cell Lymphoma Unspecified

Korea, Republic of
Ahmad Tarhini
Novartis Pharmaceuticals

Completed

Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer

Small Cell Lung Cancer

United States
Seoul National University Hospital
Abbott

Unknown

Effect and Efficacy of Xpedition™/Alpine™, Everolimus-eluting Stent for Coronary Atherosclerosis (HOST-ALPINE)

Coronary Artery Disease | Angina Pectoris | Acute Coronary Syndrome | Percutaneous Coronary Intervention

Korea, Republic of
Novartis Pharmaceuticals

Completed

AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme

Brain and Central Nervous System Tumors

United States
Technical University of Munich

Terminated

Everolimus in Treating Older Patients With Mantle Cell Lymphoma Previously Treated With First-Line or Second-Line Chemotherapy

Lymphoma

Germany
Claudio Gobbi
Ente Ospedaliero Cantonale, Ticino, Switzerland

Terminated

Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis

Multiple Sclerosis

Switzerland
University of Freiburg

Completed

Comparison of Everolimus- and Biolimus-Eluting Stents With Everolimus-Eluting Bioresorbable Vascular Scaffold Stents (EVERBIOII)

Coronary Artery Disease

Switzerland
University of South Florida
National Heart, Lung, and Blood Institute (NHLBI); National Institute of Arthritis... and other collaborators

Active, not recruiting

The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach (TAPIR)

Vasculitis | Granulomatosis With Polyangiitis | Wegener Granulomatosis

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery

Malignant Mesothelioma

United States
Dana-Farber Cancer Institute
GlaxoSmithKline; Novartis; Beth Israel Deaconess Medical Center; Brigham and Women...

Completed

Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer

Kidney Cancer | Solid Tumor

United States
St. Joseph's Healthcare Hamilton
Novartis Pharmaceuticals; McMaster University

Completed

Pilot Study of Neo-Adjuvant Everolimus to Treat Advanced Renal Cell Carcinoma - Analysis of Biomarkers

Carcinoma, Renal Cell

Canada
Northern Hospital, Australia
Abbott Medical Devices

Unknown

Apposition Assessed Using Optical Coherence Tomography of Chromium Stents Eluting Everolimus From Cobalt Versus Platinum Alloy Platforms (APPOSE)

Coronary Artery Disease

Australia
Novartis Pharmaceuticals

No longer available

A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation

Organ Transplantation

United States, Italy, Spain, United Kingdom, Germany, Taiwan, Belgium, Australia, Czechia, France, Switzerland, Norway, Canada, Brazil, Puerto Rico, Russian Federation, New Zealand, Poland, South Africa

Search clinical trials for: Prednisone Everolimus

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Liberia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations